Today: 9 June 2026
Planet Labs stock jumps again on Slovenia deal, with earnings clock ticking
27 January 2026
2 mins read

Planet Labs stock jumps again on Slovenia deal, with earnings clock ticking

New York, January 27, 2026, 14:49 EST — Regular session

  • Planet Labs shares were up about 9% in afternoon trade as traders digested a new Slovenia government agreement
  • The company said Slovenian agencies will get satellite imagery and high-resolution “tasking” services; terms were not disclosed
  • Investors are now looking to late-March earnings for clues on how fast recent government wins are turning into revenue

Planet Labs PBC (PL) shares rose about 9% on Tuesday, extending a recent run, after the satellite-imaging firm disclosed a new enterprise agreement with Slovenia’s national surveying and mapping authority. The stock was trading around $28.20 and had moved between $25.73 and $28.69 in the session.

For Planet, the timing matters. Investors have been treating contract headlines as a quick read on whether the company can turn its large imagery archive into steadier government and public-sector demand.

That’s the bet behind the trade: recurring data contracts can be sticky, but they tend to arrive in uneven chunks and are hard to model quarter to quarter. A small deal won’t fix that, but a pattern of them can.

The Slovenia agreement gives state and municipal authorities access to PlanetScope imagery and high-resolution tasking, in which customers can request fresh images over specific locations. The data is slated for agriculture monitoring, urban and infrastructure planning, and faster response to wildfires, droughts and floods. Financial terms were not disclosed.

“Our mission at GURS is to provide the highest quality geodetic and spatial data,” Tomaž Petek, director-general of Slovenia’s Surveying and Mapping Authority, said in a statement. Planet Labs Germany managing director Martin Polak said Slovenia would be working from “a single, fresh, and consistent” satellite data resource. Business Wire

Planet sells satellite imagery and geospatial products to governments and companies that need frequent views of what is changing on the ground — crops, forests, construction sites, waterways, disaster zones. The pitch is speed and coverage, not one-off pictures.

The deal also lands as European governments lean harder on remote sensing for compliance and reporting, especially around land use and climate-related risks. That push has helped lift demand for monitoring services that can be updated daily.

In the small group of publicly traded “space data” names, Planet’s closest listed peers include BlackSky Technology and Spire Global, both of which also sell data products to government and commercial customers. Planet has stood out for the scale of its imaging fleet and its push into higher-resolution tasking.

Still, there’s a catch for traders chasing the move: without contract value or duration, the market is filling in blanks. Any sign that the pipeline is thinner than the tape implies — or that deployments take longer than customers expect — can hit a stock that has been trading like a momentum name.

Next up is the calendar. Planet’s fiscal year ends January 31, and investors are looking toward the next results update, with market calendars pointing to a late-March earnings release — Investing.com lists March 26 — for clearer numbers on bookings, renewal rates and how much of these government deals are actually landing in revenue.

Stock Market Today

  • Invest in India’s Top 500 Companies with 3 Low-Cost Index Funds
    June 9, 2026, 10:10 AM EDT. Investors can access India's top 500 companies efficiently through three non-overlapping index funds: Nifty 100 (large-cap), Nifty Midcap 150, and Nifty Smallcap 250. The Nifty 100 Index Fund includes India's top 100 large-cap companies by market capitalization, spanning 17 sectors, and offers resilience in downturns. Common holdings such as HDFC Bank, Reliance Industries, and Infosys provide exposure to key economic sectors. Using these three funds prevents portfolio overlap, ensuring true diversification across market segments. Choices for Nifty 100 Index Funds include Axis, HDFC, and Bandhan, with options for systematic investment plans (SIPs). This strategy offers low cost, broad exposure, and balanced risk for investors seeking diversified growth in Indian equities.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Previous Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom

Oracle stock slides 4% as AI spending scrutiny builds ahead of Fed decision
Next Story

Oracle stock slides 4% as AI spending scrutiny builds ahead of Fed decision

Go toTop